Sharyn Lewin, MD
Gynecologic Oncology · Teaneck, NJNPI 1083862247
Payments from drug & device makers
Across 1,096 payments — averaging $2394.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$839K
- GSK$691K
- AstraZeneca$535K
- Immunogen, Inc.$144K
- AbbVie$122K
- Myriad Genetic Laboratories, Inc.$116K
- plus $176K from 12 others
What the payments were for
- Consulting fees$170,63818%
- Speaking & faculty fees$700,39972%
- Travel & lodging$79,2718%
- Food & beverage$17,6992%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 125 | $839,212 |
| GSK | 206 | $691,405 |
| AstraZeneca | 409 | $535,230 |
| Immunogen, Inc. | 59 | $144,279 |
| AbbVie | 57 | $122,343 |
| Myriad Genetic Laboratories, Inc. | 166 | $115,872 |
| Tesaro, Inc. | 13 | $68,648 |
| Genmab U.S., Inc. | 5 | $50,242 |
| Daiichi Sankyo Inc. | 36 | $38,009 |
| Astrazeneca UK Limited | 1 | $13,400 |
| Eisai Inc. | 9 | $2,580 |
| Myriad Women's Health, Inc. | 1 | $1,725 |
| Johnson & Johnson(2 entities) | 4 | $830 |
| Puma Biotechnology, Inc. | 1 | $82 |
| LSI Solutions Inc | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
| Avanos Medical | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$490,520
- JEMPERLI$141,818
- ZEJULA$90,639
- Elahere$78,000
- myChoice CDx$71,022
- PreciseTumor$36,666
- KEYTRUDA$24,855
- myRisk$7,195
- LENVIMA$2,445
- Enhertu$1,713
How this compares
$2,623,912 in reported general payments places this provider in the 95th percentile of 45 gynecologic oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Teaneck
- Maria Schiavone ForlenzaTeaneck$175K
- Eugenia GirdaNew Brunswick$4.2M
- William BurkeParamus$2M
- Christina ChuCamden$1M
- Karim ElsahwiNeptune$904K
- David WarshalCamden$575K
- Akiva NovetskyNewark$486K
- Scott RichardFlorham Park$131K
- Darlene GibbonFlorham Park$98K
- Nana TchaboMorristown$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.